Drug Pricing
Commentary
Budget Reconciliation Bill’s Healthcare Provisions Are Disastrous
Last week, House Democrats passed the $3.5 trillion budget resolution that their Senate counterparts approved earlier this month. The resolution is merely a framework, though. Over the coming months, lawmakers will write the actual legislative text of this mammoth spending bill, which could usher in the most radical changes to our healthcare ...
Drug Pricing
Watch Wayne Winegarden Discuss Drug Pricing Reform with Scripps National News
Watch Dr. Wayne Winegarden, director of PRI’s Center for Medical Economics and Innovation, discuss his recent study showing how a two-part drug pricing system would ensure prices more accurately reflect how patients value drugs with Scripps National News. The report aired on 60 television stations in 42 markets across the ...
Commentary
The Real Vaccine Skeptics Work at the FDA
Demonstrators in 50 cities across the country took the streets last month to demand a government takeover of America’s health system. The Democrats who control Washington are trying to give those activists what they’re asking for, albeit in piecemeal fashion. In recent weeks, they’ve proposed lowering Medicare’s eligibility age and adding dental, vision and hearing benefits ...
Commentary
Let’s Not Repeat Canada’s Healthcare Mistakes
Demonstrators in 50 cities across the country took the streets last month to demand a government takeover of America’s health system. The Democrats who control Washington are trying to give those activists what they’re asking for, albeit in piecemeal fashion. In recent weeks, they’ve proposed lowering Medicare’s eligibility age and adding dental, vision and hearing benefits ...
Drug Pricing
Watch PRI, Pioneer Institute Webinar on ICER, health care innovation
The Pioneer Institute and Pacific Research Institute hosted an educational webinar on the importance of protecting treatment access, innovation, and equity as Washington addresses drug pricing reforms on July 19, 2021. Pioneer Institute, PRI, and special guests explored the current policy landscape on treatment value and access and how policy ...
Commentary
America’s drug rebate system is broken
Rebates and discounts are generally viewed as important competitive tools that lower prices for consumers, and rightly so. But consumers should beware when discounts create competitive restrictions that reduces their choices and increases their costs. Such is the case when dominant drug manufacturers use rebates to keep lower-priced drugs off ...
Blog
To See the Fallacy of H.R. 3 (Lower Drug Costs Now Act) Just Look at the Inflation Data
Railing about sky high drug prices makes good political theater and helps drum up support for the latest attempt to impose drug price controls (H.R. 3 or the Lower Drug Costs Now Act). This accusation also perpetuates misinformation. If implemented, H.R. 3 would endanger patient access to current efficacious medicines ...
Commentary
Government Health Insurance: An Offer Businesses Should Refuse
Executives at many large corporations want the government to take on a greater role providing health coverage and controlling costs, according to a new Kaiser Family Foundation survey. That seems to indicate big business is sympathetic to the core of the Democrats’ healthcare agenda, including the idea of a public option ...
Commentary
Democratic drug pricing bill is a house of cards
House Democrats just introduced H.R. 3, a bill that would allow the government to cap drug prices based on what they cost in six other developed nations. President Joe Biden is sympathetic to the idea. In his speech to Congress this week, he called for giving the federal government the power to negotiate drug ...
Commentary
With HR 3, House Democrats Lose Their Grip on Reality
Last week, House Democrats introduced H.R. 3, a bill that would empower the federal government to set prescription drug prices for the entire U.S. pharmaceutical market. The measure comes at the worst possible time. The rapid development of effective vaccines against COVID-19 has demonstrated what can happen when the drug industry ...
Budget Reconciliation Bill’s Healthcare Provisions Are Disastrous
Last week, House Democrats passed the $3.5 trillion budget resolution that their Senate counterparts approved earlier this month. The resolution is merely a framework, though. Over the coming months, lawmakers will write the actual legislative text of this mammoth spending bill, which could usher in the most radical changes to our healthcare ...
Watch Wayne Winegarden Discuss Drug Pricing Reform with Scripps National News
Watch Dr. Wayne Winegarden, director of PRI’s Center for Medical Economics and Innovation, discuss his recent study showing how a two-part drug pricing system would ensure prices more accurately reflect how patients value drugs with Scripps National News. The report aired on 60 television stations in 42 markets across the ...
The Real Vaccine Skeptics Work at the FDA
Demonstrators in 50 cities across the country took the streets last month to demand a government takeover of America’s health system. The Democrats who control Washington are trying to give those activists what they’re asking for, albeit in piecemeal fashion. In recent weeks, they’ve proposed lowering Medicare’s eligibility age and adding dental, vision and hearing benefits ...
Let’s Not Repeat Canada’s Healthcare Mistakes
Demonstrators in 50 cities across the country took the streets last month to demand a government takeover of America’s health system. The Democrats who control Washington are trying to give those activists what they’re asking for, albeit in piecemeal fashion. In recent weeks, they’ve proposed lowering Medicare’s eligibility age and adding dental, vision and hearing benefits ...
Watch PRI, Pioneer Institute Webinar on ICER, health care innovation
The Pioneer Institute and Pacific Research Institute hosted an educational webinar on the importance of protecting treatment access, innovation, and equity as Washington addresses drug pricing reforms on July 19, 2021. Pioneer Institute, PRI, and special guests explored the current policy landscape on treatment value and access and how policy ...
America’s drug rebate system is broken
Rebates and discounts are generally viewed as important competitive tools that lower prices for consumers, and rightly so. But consumers should beware when discounts create competitive restrictions that reduces their choices and increases their costs. Such is the case when dominant drug manufacturers use rebates to keep lower-priced drugs off ...
To See the Fallacy of H.R. 3 (Lower Drug Costs Now Act) Just Look at the Inflation Data
Railing about sky high drug prices makes good political theater and helps drum up support for the latest attempt to impose drug price controls (H.R. 3 or the Lower Drug Costs Now Act). This accusation also perpetuates misinformation. If implemented, H.R. 3 would endanger patient access to current efficacious medicines ...
Government Health Insurance: An Offer Businesses Should Refuse
Executives at many large corporations want the government to take on a greater role providing health coverage and controlling costs, according to a new Kaiser Family Foundation survey. That seems to indicate big business is sympathetic to the core of the Democrats’ healthcare agenda, including the idea of a public option ...
Democratic drug pricing bill is a house of cards
House Democrats just introduced H.R. 3, a bill that would allow the government to cap drug prices based on what they cost in six other developed nations. President Joe Biden is sympathetic to the idea. In his speech to Congress this week, he called for giving the federal government the power to negotiate drug ...
With HR 3, House Democrats Lose Their Grip on Reality
Last week, House Democrats introduced H.R. 3, a bill that would empower the federal government to set prescription drug prices for the entire U.S. pharmaceutical market. The measure comes at the worst possible time. The rapid development of effective vaccines against COVID-19 has demonstrated what can happen when the drug industry ...
